Giovanni Adami

University of Verona

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (29)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Antonio Carletto

Professor of Practice

University of Verona

ITALY

View details

Thomas Funck-Brentano

Professor

Université Paris Cité

FRANCE

View details

Paolo Gisondi

University of Verona

ITALY

View details

Gloria Porcu

University of Milano-Bicocca

ITALY

View details

Angelo Fassio

Università degli Studi di Torino

ITALY

View details

Maurizio Rossini

Director/Prof

University of Verona

ITALY

View details

Matteo Gatti

University of Verona

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Giovanni Adami

Research Interests

Explore related searches

Contact this professor

Articles (29)

Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis

Bone mineral density is associated with pre-treatment pain levels of complex regional pain syndrome type 1 and predicts the response to N-containing bisphosphonates.

Increased serum IgG antibody response to Merkel cell polyomavirus oncoproteins in patients with autoimmune rheumatic diseases.

Glucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis

Environmental Exposure to Particulate Matter 10 and Mycosis Fungoides: No Evidence of Increased Risk.

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis.

Long-Term Changes in Parameters of Bone Quality in Kidney Transplant Recipients Treated with Denosumab.

Impact of particulate matter exposure on melanoma risk: A multicentre case–control study

Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study

Impact of Exposure to Environmental Particulate Matter on the Onset of Giant Cell Arteritis

Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases

Novel genetic mutation associated with hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome treated with denosumab: a case report

Clinical Images: Erosive tophaceous gout and uric acid nephrolithiasis: microscopic and three‐dimensional high‐resolution peripheral quantitative computed tomography findings

New point-of-care calcaneal ultrasound densitometer (Osteosys BeeTLE) compared to standard dual-energy X-ray absorptiometry (DXA).

Post-diagnosis serum 25-hydroxyvitamin D concentrations in women treated for breast cancer participating in a lifestyle trial in Italy.

The sequential antifracturative treatment: a meta-analysis of randomized clinical trials

Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement

Response to: ‘Correspondence on ‘Gender disparity in authorship of guidelines and recommendations in rheumatology’’ by Stewartet al

Patients with osteoporosis: Children of a lesser god

Bone Loss in Inflammatory Rheumatic Musculoskeletal Disease Patients Treated With Low‐Dose Glucocorticoids and Prevention by Anti‐Osteoporosis Medications

Patients with osteoporosis: children of a lesser god

Response to: `Correspondence on 'Gender disparity in authorship of guidelines and recommendations in rheumatology'' by Stewart et al

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)

Association between acute exposure to environmental air pollution and fragility hip fractures

Cardiovascular Safety of Romosozumab: New Insights from Postmenopausal Women with Chronic Kidney Disease

Long-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome.

Machine learning to characterize bone biomarkers profile in rheumatoid arthritis.

Refracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials.

Collaborators (7)

Antonio Carletto

Thomas Funck-Brentano

Paolo Gisondi

Gloria Porcu

Angelo Fassio

Maurizio Rossini

Matteo Gatti

Make your next move.